DOCSLIB.ORG

Orally Disintegrating Compositions of Emoxypine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Orally Disintegrating Compositions of Emoxypine (19) & (11) EP 2 248 516 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.11.2010 Bulletin 2010/45 A61K 9/00 (2006.01) A61K 9/20 (2006.01) A61K 31/44 (2006.01) (21) Application number: 10162059.9 (22) Date of filing: 05.05.2010 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • Toksöz, Ahmet GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 34398, Istanbul (TR) PL PT RO SE SI SK SM TR • Cifter, Ümit Designated Extension States: 34398, Istanbul (TR) BA ME RS • Türkyilmaz, Ali 34398, Istanbul (TR) (30) Priority: 06.05.2009 TR 200903548 (74) Representative: Sevinç, Erkan (71) Applicant: Sanovel Ilac Sanayi ve Ticaret A.S. Istanbul Patent & Trademark Consultancy Ltd. 34398 Istanbul (TR) Plaza-33, Büyükdere cad. No: 33/16 Sisli 34381 Istanbul (TR) (54) Orally disintegrating compositions of emoxypine (57) The present invention is related to an orally disintegrating composition comprising emoxypine or a pharmaceu- tically acceptable salt thereof and one or more pharmaceutically acceptable excipient. EP 2 248 516 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 2 248 516 A1 2 Description ative formulation contains emoxypine succinate and aux- iliary agents in core and a coating layer. The auxiliary Technical Aspect agents in the core comprise kaolin, potato starch, calcium stearate, stearic acid, talc and methyl cellulose. The coat- [0001] The present invention is related to an orally dis- 5 ing layer contains titanium dioxide and serge 80. integrating composition comprising emoxypine or a phar- [0007] In prior art, there are also several patents which maceutically acceptable salt thereof and one or more disclose orally disintegrating compositions but none of pharmaceutically acceptable excipient. them includes emoxypine or a pharmaceutically accept- able salt thereof. Background of the Invention 10 [0008] Orally disintegrating dosage forms are becom- ing an increasingly important issue in the area of better [0002] Emoxypine is a heteroaromatic antioxidant patient compliance comparative to the conventional solid which has a membranoprotective, nootropic and seda- dosage forms for oral administration such as capsules tive action. Its chemical name is 2-ethyl-6-methyl-3-hy- and tablets, which are the most commonly used. In par- droxypyridine and its chemical structure is shown in the 15 ticular pediatric and geriatric patients, and patients with Formula I. mental problems and non- compliant patients often ex- perience difficulties in swallowing solid dosage forms. Besides, conventional solid dosage forms are not suita- ble for bedridden or busy and travelling patients, in case 20 the patient may not have easy access to water. Thus, orally disintegrating compositions represent an alterna- tive for such patients and provide for a better patient com- pliance with recommended pharmaceutical therapies. In addition, medicaments which may be used for sedatives, 25 hypnotics, and antipsychotic are amendable such dos- age forms. [0009] Additionally oral administration of the drugs is difficult in patients having concomitant vomiting, nausea or diarrhoea. The orally disintegrating dosage form is one 30 of the advantageous methods to deliver the drugs to such [0003] Its aromatic activity range is very wide such as patients. By administering the orally disintegrating dos- increasing the stress resistance of organism. It acts as age forms, faster absorption of the drug occurs through the anxiolytic which doesn’t cause sleepiness or doesn’t buccal mucosa and it may reduce the first pass metab- have myorelaxant effect; its nootropic properties prevent olism leading to better efficacy of the drug. This dosage and reduce learning and memory defects in patients of 35 form enhances the clinical effects of some drugs by lead- old age under pathogenic factors. One of the activities ing to an increase in bioavailability and a reduction in of emoxypine is its anticonvulsant activity which shows side effects because of avoidance of first- pass liver me- antioxidant and antihypoxic properties. It increases the tabolism. attention concentration and capacity for work and de- [0010] It is difficult to develop orally disintegrating com- creases the toxic affect of alcohol. It inhibits peroxide 40 positions because of several different reasons. A satis- oxidation of lipids, increases the superoxidoxidase activ- fied orally disintegrating dosage form needs to meet a ity and elevates the ratio of lipid-protein. Also, provides number of requirements. Firstly, it has to disintegrate in a higher dopamine concentration in brain. the mouth spontaneously. The time in which a dosage [0004] Emoxypine is marketed under the brand name form must dissolve or disintegrate in the oral cavity is MEXIDOL®and it is administered orally in a therapeutic 45 necessarily much shorter than in the stomach. Moreover, dose from 125 mg to 250 mg, three times a day and it a premature release in the mouth could also lead to prob- has injectable formulations containing 50mg/ml in 2 ml lems due to the often unpleasant taste of the active in- and 5ml ampules in IV/IM forms. gredient. Besides, these compositions should be very [0005] Injectable and drop solutions of emoxypine HCl porous and should not be very hard. These porous com- were disclosed in US patent no 4,486,440 in 17.08.1983. 50 positions tend to be very sensitive to humidity. As a con- They are used as retinoprotector for treating intraocular sequence, they may have some stability problems. hemorrhage, myopic chorioretinal dystrophies, congen- [0011] To fulfill all these requirements the formulation ital retinal dystrophies, retinal burns and prevention of for a specific drug needs to be adapted in particular by injury in lasercoagulation. a careful selection of the excipients used. However, the [0006] A conventional tablet formulation of emoxypine 55 excipients selected may lead to formulations which are succinate (Mexidol ®) is described in PCT application WO not bioavailable to the corresponding conventional dos- 96/02238 A1, Aktsionernoe Obschestvo Zakrytogo Tipa age forms. Thus, they have to be chosen very carefully. ’Olvik’, 15.07.1994. The proposed neurotropic and sed- [0012] Additionally, precautions have to be taken at 2 3 EP 2 248 516 A1 4 the preparation, packaging, handling and storing of the collate and the like and mixtures thereof; preferably finished dosage forms of orally disintegrating composi- crosscarmellose sodium and/or crospovidone. tions since they tend to be both hygroscopic and friable. [0022] It has unexpectedly found that in this orally dis- [0013] Thus, a need rises for orally disintegrating com- integrating composition having a weight ratio of emox- positions of emoxypine or a pharmaceutically acceptable 5 ypineto super disintegrants, particularly crosscarmellose salt, which overcomes above described problems and sodium, in the range of between 1:10 and 10:1 (w/w), which further provide the advantageous property of al- has a synergistic effect over the disintegration time. Pref- lowing the active medicament to disintegrate or dissolve erably the range is between 1:5 and 5:1 (w/w). in the oral cavity without remaining substantial amounts [0023] In one embodiment, the amount of crosscar- of the active ingredient. 10 mellose sodium is present about 0.1 to 30% by weight of total composition; preferably it is about 2 to 10% by Description of the invention weight of total composition. [0024] In another embodiment, the amount of [0014] The main embodiment of the present invention crospovidone is about 0.1 to 20 % by weight of total com- is to provide a novel orally disintegrating composition 15 position; preferably it is about 2 to 10 % by weight of total comprising emoxypine or a pharmaceutically acceptable composition. salt thereof and one or more pharmaceutically accepta- [0025] Suitable diluents may include but not limited to ble excipient which overcomes the above described lactose, microcrystalline cellulose, mannitol, spray- dried problems in prior art and have additive advantages over mannitol, starch,sodium carbonate, sodium bicarbonate, them. 20 calcium carbonate and the like and mixtures thereof; pref- [0015] It has unexpectedly been found that the specific erably spray-dried mannitol and/or microcrystalline cel- combination of the emoxypine with the combination of lulose. the super disintegrants provides an orally disintegrating [0026] It is reported that, spray-dried mannitol, has composition which avoids the afore-mentioned disad- physical chemical properties that make it ideal for con- vantages of the orally disintegrating compositions of the 25 stituting the appropriate diluent for this invention. Be- prior art. cause it dissolves easily and quickly in a little amount of [0016] According to the invention an emoxypine orally water or saliva and its disintegrating rate is much faster disintegrating composition is provided which is funda- than powder mannitol and other related saccharine ex- mentally comparable with the existing regular conven- cipients. It is highly compressible and it has optimum flu- tional solid dosage forms such as tablets or capsules, 30 idity for direct compression processes. It has good dilu- however with the unexpected benefits found with oral tion capacity due to the size and form of the particle, disintegration. which makes it possible to accept large amounts of active [0017] In one embodiment the orally disintegrating ingredients that are not easily compressed. It is chemi- composition of emoxypine
Load more

Recommended publications
  • Abuse-Proof Solid Pharmaceutical Composition
    (19) TZZ¥¥ ¥_T (11) EP 3 329 939 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 06.06.2018 Bulletin 2018/23 A61K 47/02 (2006.01) A61K 47/36 (2006.01) A61K 9/16 (2006.01) A61K 31/485 (2006.01) (2006.01) (21) Application number: 17204525.4 A61K 31/192 (22) Date of filing: 29.11.2017 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • BOSCHETTI, Silvia GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO I-38060 Aldeno (TN) (IT) PL PT RO RS SE SI SK SM TR • ROSSI, Massimiliano Designated Extension States: I-38121 Trento (IT) BA ME • BENFENATI, Diego Designated Validation States: I-38052 Caldonazzo (TN) (IT) MA MD • POJER, Alessandro I-38092 Altavalle (TN) (IT) (30) Priority: 02.12.2016 IT 201600122469 (74) Representative: Allaix, Roberto (71) Applicant: E-Pharma Trento S.p.A. PGA S.p.A. 38123 Trento (IT) Via Mascheroni, 31 20145 Milano (IT) (54) ABUSE-PROOF SOLID PHARMACEUTICAL COMPOSITION (57) The present invention relates to an abuse-proof solid pharmaceutical composition comprising an active ingre- dient with potential for abuse, silica in an amount of from 10 mg to 1000 mg, guar flour in an amount of from 100 mg to 300 mg, and a water soluble diluent in an amount of from 500 mg to 5000 mg. EP 3 329 939 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 329 939 A1 Description FIELD OF THE INVENTION 5 [0001] The present invention relates to an abuse-proof solid pharmaceutical composition, in particular a solid phar- maceutical composition, such as, for example a granulate or a tablet, capable of solubilizing in a glass of water (about 100 ml), but of forming a not injectable gel and/or viscous solution if added to the amount of water contained in a hypodermic syringe (about 10 ml).
    [Show full text]
  • Farmaatsia- Terminoloogia Teine, Täiendatud Trükk
    Farmaatsia- terminoloogia Teine, täiendatud trükk Graanulid Suspensioon Lahus Emulsioon Pillid Pulber Salv Kreem Aerosool Plaaster Sprei Pastill Tampoon Oblaat Emulsioon Kontsentraat Silmageel Tablett Haavapulk Ninatilgad Kapsel Lakukivi Inhalaator Farmaatsia- terminoloogia Teine, täiendatud trükk Tartu 2019 Koostajad: Toivo Hinrikus, Karin Kogermann, Ott Laius, Signe Leito, Ain Raal, Andres Soosaar, Triin Teppor, Daisy Volmer Keeletoimetaja: Tiina Kuusk Kirjastanud: Ravimiamet Nooruse 1, 50411 Tartu Telefon: +372 737 4140 Faks: +372 737 4142 E-post: [email protected] Esimene trükk 2010 Teine, täiendatud trükk 2019 Raamat on leitav Ravimiameti veebilehelt: www.ravimiamet.ee/farmaatsiaterminoloogia Väljaande refereerimisel või tsiteerimisel palume viidata allikale. ISBN 978-9949-9697-3-9 Sisukord Farmaatsiaterminoloogia Eestis..........................................................................................5 Üldised farmaatsiaalased terminid ...................................................................................10 Euroopa farmakopöa ......................................................................................................... 21 Euroopa farmakopöa sõnastik ..........................................................................................24 Standardterminid ..............................................................................................................29 Ravimvormid .....................................................................................................................29
    [Show full text]
  • SR.NO. PRODUCT NAME 1 Palonosetron Hydrochloride
    SR.NO. PRODUCT NAME 1 Palonosetron Hydrochloride Injection 0.05mg/ml 2 Esomeprazole Sodium For Injection 40mg 3 Cimetidine Injection 100mg/ml 4 Ivermectin 1% and Clorsulon 10% 5 Levamisole Hydrochloride+Oxyclozanide 3%w/v+6%w/v 6 Closantel and Levamisole Injection 50mg + 100mg/ml 7 Levamisole Hydrochloride and Rafoxanide Injection 30mg + 45mg/ml 8 Levamisole Hydrochloride Injection 100mg/ml 9 Praziquantel Injection 56.8 mg/ml 10 Doramectin Injection 10mg 11 Lorazepam Injection 4mg/ml 12 Diazepam Injection 5mg/ml 13 Midazolam Injection BP 5mg/ml (Single Use) 14 Diazepam Injection 10 mg./ml. 15 Temocillin Injection 1gm 16 Rifampicin For Injection 300mg 17 Spectinomycin for Injectable suspension 2g 18 Placentrex Injection 2ml 19 Amoxicillin and Potassium Clavulanate Injection BP 625mg 20 Amoxicillin and Potassium Clavulanate For Inj. 1000mg+200mg 21 Amoxicillin Sodium For Injection 250 mg. 22 Amoxicillin Sodium For Injection 500 mg. 23 Amoxicillin Sodium With Cloxacillin Sodium For Injection 1000 mg. + 1000 mg. 24 Amoxicillin Sodium and Cloxacillin Sodium For Injection 250 mg. + 250 mg. 25 Amoxicillin Sodium With Cloxacillin Sodium For Injection 500 mg. + 500 mg. 26 Amoxicillin With Cloxacillin For Injection 1500+1500 mg 27 Amoxicillin With Cloxacillin For Injection 2000+2000mg 28 Amoxicillin Sodium and Clavulanate Potassium for Injection 1200 mg 29 Ampicillin Sodium For Injection 2000 mg. 30 Ampicillin Sodium For Injection 3000 mg. 31 Ampicillin Sodium For Injection 250 mg. 32 Ampicillin Sodium For Injection 2500 mg. 33 Ampicillin Sodium For Injection 500 mg. 34 Ampicillin Sodium With Cloxacillin Sodium For Injection 1250+1250 mg 35 Ampicillin and Cloxacillin For Injection Vet 1.5gm+1.5gm 36 Ampicillin Sodium With Cloxacillin Sodium For Injection 1000 mg.
    [Show full text]
  • Mexidol® Action
    Mexidol has antioxidant, antihypoxic and membrane-protective Mexidol® action. It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces International Non-Proprietary Name (INN): Mexidol the viscosity of the membrane and increases its fluidity. The drug (Emoxypine) modulates the activity of membrane-bound enzymes (calcium of independent phosphodiesterase, adenylate cyclase and Dosage Form: pills (125 mg) acetylcholinesterase) and receptor complexes (benzodiazepine, Structure: 1 capsule contains: GABA and acetylcholine): it enhances their ability to bind to Active ingredient: ethylmethylhydroxypyridine succinate (2-ethyl- ligands, helps to preserve the structural and functional 6-methyl-3-hydroxypyridine) – 125 mg. organization of biomembranes and neurotransmitter transport, Excipients: lactose monohydrate – 97.5 mg, povidone – 25 mg, and facilitates synaptic transmission improvement. magnesium stearate – 2.5 mg. Mexidol causes an increase of dopamine in the brain. It Film coat: opadrai II white 33G28435 – 7.5 mg (hypromellose 3 enhances compensatory activation of aerobic glycolysis and mg, titanium dioxide – 1.875 mg, lactose monohydrate – 1.575 weakens the inhibition of oxidative processes in the Krebs cycle mg, polyethylene glycol (macrogol) – 0.6 mg, triacetin – 0.45 mg) under conditions of hypoxia with an increased ATP and creatine phosphate. The drug activates the energy-synthesizing functions Description: of mitochondria and stabilization of cell membranes. The double radius pills are covered with a film coat in white or Mexidol improves the metabolism and blood supply of the brain, light creamy colour. On the cross-section there are two layers: improves microcirculation and rheological properties of blood, the inner one (the core) is gray or gray-creamy and the outer one and reduces platelet aggregation.
    [Show full text]
  • WO 2017/120012 Al 13 July 20 17 (13.07.2017) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/120012 Al 13 July 20 17 (13.07.2017) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/185 (2006.01) A61K 31/336 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/US20 16/067024 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 15 December 2016 (15. 12.2016) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (25) Filing Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: ZA, ZM, ZW. 62/275,182 5 January 2016 (05.01 .2016) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: THE REGENTS OF THE UNIVERSITY kind of regional protection available): ARIPO (BW, GH, OF CALIFORNIA [US/US]; 1111 Franklin Street, 12th GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Floor, Oakland, California 94607-5200 (US).
    [Show full text]
  • Anapharm Bioanalytics Method List
    Bioanalytical Method List SEPTEMBER 2021 Anapharm Bioanalytics Encuny 22, 2nd floor 08038 Barcelona, Spain T. +34 93 223 86 36 [email protected] www.anapharmbioanalytics.com Page 1 / 19 Newly developed or recently updated methods Compound Platform Calibration Range Biological Matrix Canagliflozin UPLC/MS/MS 10-4000 ng/mL Human EDTA Plasma Cholecalciferol (Vitamin D3) LC/MS/MS 0.15-15 ng/mL Human EDTA Plasma Clozapine LC/MS/MS 0.1-50 ng/mL Human EDTA Plasma Dapagliflozin LC/MS/MS 0,5-200 ng/mL Human EDTA Plasma Disulfiram UPLC/MS/MS 0.5-100 ng/mL Human EDTA Plasma Edaravone LC/MS/MS 2-7000 ng/mL Human EDTA Plasma L-Ascorbic Acid LC/MS/MS 100 - 25000 ng/mL Human Lithium Heparinized Plasma Mirabegron UPLC/MS/MS 0.1-100 ng/mL Human EDTA Plasma Olodaterol UPLC/MS/MS 0.2-50 pg/mL Human EDTA Plasma Ramipril; Ramiprilat UPLC/MS/MS 0.2-80 ng/mL; 0.2-80 ng/mL Human EDTA Plasma Riluzole LC/MS/MS 1-1000 ng/mL Human EDTA Plasma Silodosin UPLC/MS/MS 0.2-100 ng/mL Human EDTA Plasma Silodosin Glucuronide UPLC/MS/MS 0.5-200 ng/mL Human EDTA Plasma Temozolomide UPLC/MS/MS 100–25000 ng/mL Human EDTA Plasma Ticagrelor LC/MS/MS 2–1000 ng/mL Human EDTA Plasma Torasemide LC/MS/MS 10-5000 ng/mL Human EDTA Plasma www.anapharmbioanalytics.com Page 2 / 19 List of bioanalytical methods Compound Platform Calibration Range Biological Matrix Abiraterone LC/MS/MS 0.2-100 ng/mL Human EDTA Plasma Abiraterone LC/MS/MS 0.5-200 ng/mL Human EDTA Plasma Aceclofenac LC/MS/MS 15-15000 ng/mL Human EDTA Plasma Acetylsalicylic Acid; Salicylic Acid LC/MS/MS 10-5000 ng/mL;
    [Show full text]
  • An Overview on Non Epileptic Seizures
    wjpmr, 2017,3(7), XXX-XXX SJIF Impact Factor: 4.103 WORLD JOURNAL OF PHARMACEUTICAL Research Article ISSN 2455-3301 AND MEDICAL RESEARCH www.wjpmr.com WJPMR wjpmr, 2017,3(7), 185-193 SJIF Impact Factor: 4.103 WORLD JOURNAL OF PHARMACEUTICAL Research Article Aishwarya et al. World Journal of Pharmaceutical and Medical ReISSNsearch 2455 -3301 AND MEDICAL RESEARCH www.wjpmr.com WJPMR AN OVERVIEW ON NON EPILEPTIC SEIZURES M. N. L. Aishwarya*, Prasanna Kumar Kar, P. C. Jayanth and M. Niranajan Babu Department of Pharmacology, Seven Hills College of Pharmacy, Tirupati. *Corresponding Author: M. N. L. Aishwarya Department of Pharmacology, Seven Hills College of Pharmacy, Tirupati. Article Received on 14/06/2017 Article Revised on 05/07/2017 Article Accepted on 26/07/2017 ABSTRACT The brain is susceptible to many different types of disorders that strike at every stage of life. Developmental disorders such as autism and dyslexia first appear in early childhood. Psychiatric diseases such as depression and schizophrenia are typically diagnosed in teens or in early adulthood. Epilepsy is the fourth most common neurological disorder and affects people of all ages. Epilepsy is a group of related disorders characterized by a tendency for recurrent seizures that occur due to abnormal electrical discharges whereas Non Epileptic Seizures are not characterized by abnormal electric discharges in brain. Non Epileptic Seizures also possess greater impact on human life as that of normal epilepsy. This article aims towards discussing Non Epileptic Seizures in detail which includes the classification, epidemiology, types, causes, diagnosis, and treatment of Non Epileptic Seizures including treatment of Pediatric Non Epileptic Seizures.
    [Show full text]
  • Capsules Gastro- Resistant 40Mg, in Blister (7/1X7/, 14/2X7/, 15/3X5/, 28
    40mg, KRKA d.d., Novo KRKA d.d., Novo esomeprazole in blister (7/1x7/, 14/2x7/, capsules gastro- mesto, Smarjeska 06.02.2015 mesto, Smarjeska 1554 Emanera (esomeprazole 15/3x5/, 28/4x7/, Slovenia A02BC05 14185 PoM resistant cesta 6, 8501 Novo 06.02.2020 cesta 6, 8501 Novo magnesium) 30/3x10/, 56/8x7/, Mesto Mesto, Slovenia 60/6x10/) Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem - secondary packager, Schering-Plough batch releaser (bulk Central East AG, fosaprepitant powder lyophilized manufacturer, 150mg, 19.08.2016 Weystrasse 20, P.O. 1555 Emend (fosaprepitant for solution for primary packager - the Netherlands A04AD12 12302/3 PoM 10ml glass vial 22.03.2018 Box CH-6000 dimeglumine) infusion Patheon Lucerne 6, Manufacturing Switzerland Services LLC, 5900 Martin Luther King Jr. Higway, Greenville, North Carolina 27834, USA) Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem - secondary packager, Schering-Plough batch releaser (bulk Central East AG, fosaprepitant powder lyophilized manufacturer, 150mg, 08.08.2017 Weystrasse 20, P.O. 1556 Emend (fosaprepitant for solution for primary packager - the Netherlands A04AD12 16883 PoM 10ml glass vial (1) 08.08.2022 Box CH-6000 dimeglumine) infusion Patheon Lucerne 6, Manufacturing Switzerland Services LLC, 5900 Martin Luther King Jr. Higway, Greenville, North Carolina 27834, USA) 341 Belmedpreparaty Belmedpreparaty 10mg/ml, 07.10.2013 RUE (220007, Minsk, 1557 Emoxypine emoxipine drops eye (solution) RUE (220007, Minsk, Belarus S01XA 12895 PoM 5ml glass vial 07.10.2018 Fabritsius
    [Show full text]
  • Belmedpreparaty, RUE Fabriciusa St
    Belmedpreparaty, RUE Fabriciusa st. 30, 220007 Minsk, Republic of Belarus Tel/Fax: (+375 17) 217 13 28 [email protected] www.belmedpreparaty.by Dear Sirs, Please accept our sincere regards and respect. «Belmedpreparaty» - the leading pharmaceutical enterprise in the Republic of Belarus, since 1929. The enterprise is the leading one among all the pharmaceutical enterprises in the Republic of Belarus in production capacities and supplying of pharmaceutical products .The enterprise produces 360 sorts of pharmaceutical products of different pharmacological groups. «Belmedpreparaty» has modern high-technology equipment and is the leader in the manufacture of the following pharmaceutical products: - Insulin; - Products for the cancer and tuberculosis treatment; - Narcotic products and Psychotropic substances; - Antibiotics and other has been issuing almost all types of dosage forms: - Tablets with different coating, and without them; - Hard and soft gelatin capsules; - Solutions for injection and infusion in vials and ampoules; - Lyphilisaited and sterile packaged powders for injections and infusions; - Eye drops; - Ointments, creams and gels. The important place of the enterprise’ product list belongs to anticancer products: Fludarobel, Leucladine, Methotrexate, Paclitaxel, Cytarabine, Oxaliplatin, Zoledronic acid and others. Especially the enterprise is proud of the original medicine for photodynamic therapy of oncological diseases - Photolon. Manufacture of pharmaceutical products is certified for compliance with GMP, the enterprise implemented a quality management system in compliance with ISO 9001-2001. «Belmedpreparaty» is supplying products to 14 countries, such as Russia, the Ukraine, Kazakhstan, Azerbaijan, Vietnam, Iraq, USA and others. We are truly interested in developing our export potential, market development and inviting you to collaborate with us in the following directions: 1.
    [Show full text]
  • Substance Abuse in the Workplaces of Our Bodies and Mind
    “Turn on, Tune in, Drop out “ Substance Abuse in the Workplaces of our bodies and mind.. Warren Silverman MD Brief History of Drug abuse – Mary Jane 1629 – Marijuana introduced to the Puritan colonies of New England 1765 – George Washington was cultivating Marijuana for a sore tooth 1800’s Tincture of Cannabis is available from pharmacies, unpopular due to variations in potency and dosage, but recreational use continues with Hashish clubs in most cities by 1885 By the 20th century, marijuana use was associated with racial groups and drug abusers and lost popularity The foreign origin of marijuana lead to propaganda against its use (as we have just seen), by 1930’s marijuana was considered wicked In the 1960’s, drug use was considered a demonstration of anti-establishment leanings and became popular Marijuana has remained a constant presence in our society with gradual legislation to decriminalize and legitimize its use Brief History of Drug Abuse - Opiates In colonial America, Opiate medications were common in London and imported to the colonies – used to treat pain from diarrhea, colds, fever, tooth aches, cholera, rheumatism, pelvic disorders, athlete’s foot and baldness 1784 Dr. William Buchan’s book tells people how to make their own tincture of Opium (paregoric) to keep around the house 1804 catalogue listed 90 brands of elixir, by 1905 it was more than 28,000 1803 Morphine developed (Morpheus – god of dreams) Hypodermic needle invented and by the civil war Morphine was widely used as injectable 1898 Heroin developed
    [Show full text]
  • Drugsson Partners Produktlista
    DRUGSSON № Product Name Dosage Release form Amount in packing INN (or composition) 1 Acetylcysteine 0.2g powder for oral solution, sachet 20 Acetylcysteine 2 Acetylcysteine 20% 5ml solution for inhalation 10 Acetylcysteine 3 Acetylsalicylic acid 500mg tablets 20 Acetylsalicylic acid 4 Acetylsalicylic acid 50mg lyophilized powder for solution for injection 1 Acetylsalicylic acid 5 Acidin-Pepsin tablets 50 Betain + Pepsin 6 Acyclovir 250mg freeze-dried powder for injection, vial 1 Acyclovir 7 Acyclovir 500mg freeze-dried powder for injection, vial 1 Acyclovir 8 Acyclovir 1000mg freeze-dried powder for injection, vial 1 Acyclovir 9 Acyclovir 50mg/g 5g ointment 1 Acyclovir 10 Acyclovir 200 mg tablets 20 Acyclovir 11 Aevit capsules 50 Vitamin A and E 12 Aktovir 4g ointment 1 Acyclovir + Butaminophene 13 Alendronic acid 70mg tablets 4 Alendronic acid Bile + Garlic + Nettle leaves 14 Allochol coated tablets 50 + Activated Carbon 15 Alpha-tocopherol acetate 100mg capsules 30 Vitamin E Ferric Chloride Hexahydrate, 16 Alustat 10ml solution for external use, vial 1 Aluminium Chloride Hexahydrate Amoxicillin + beta-lactamase 17 Amklav 500 mg+100 mg powder for solution for intravenous use, vial 1 inhibitor Amoxicillin + beta-lactamase 18 Amklav 1000 mg+200 mg powder for solution for intravenous use, vial 1 inhibitor Amoxicillin + beta-lactamase 19 Amklav 250 mg+125 mg coated tablets, vial 15 inhibitor 20 Amlodipine 5mg tablets 30 Amlodipine 21 Amoxicillin 250mg capsules 30 Amoxicillin 22 Ampicillin trihydrate 250mg tablets 20 Ampicillin trihydrate 23 Analgin 500mg tablets 20 Metamizole sodium 24 Anastrozole 1mg coated tablets 30 Anastrozole 25 Artificial tear 1ml eye drops, dropping tubes 2 Hypromellose + Dextran 26 Ascorbic acid 25 mg tablets 20 Ascorbic acid 27 Ascorbic acid with glucose 100 mg/ 877 mg tablets 20 Ascorbic acid + Glucose Potassium aspartate.
    [Show full text]
  • 244 Original Article: Features of Leukocytes' Apoptosis And
    Bangladesh Journal of Medical Science Vol. 18 No. 02 April’19 Original article: Features of leukocytes’ apoptosis and emoxypine succinate efficacy in case of combined trauma of the chest and both thighs in rats Inna Krynytska1, Mariya Marushchak2, Liudmyla Holovatiuk3, Leonid Shkrobot4, Natalia Sokhor5, Julia Stepas6 Abstract: Objective: This study aims to establish features of blood leukocytes’ apoptosis and substantiate the efficacy of emoxypine succinate applying in case of combined trauma of the chest and both thighs in rats. Materials and Methods: Analysis of cell samples to determine reactive oxygen species was evaluated by the flow laser cytometry method, using 2.7-dichlorodihydrofluorescein diacetate (Sigma Aldrich, Germany). The number of leukocytes with low mitochondrial transmembrane potential was evaluated by the flow laser cytometry method, using a kit of reagents «MitoScreen» («BD Pharmingen», USA). The number of apoptotic leukocytes was evaluated by the flow laser cytometry method, using a kit of reagents “ANNEXIN V FITC” (“Beckman Coulter”, USA). Emoxypine succinate to animals was injected intraperitoneally 1 time per day during 14 days from the first day of experiment in the dosage of 40 mg/kg. Results and Discussion: It was established the progressive, statistically significant increasing of Annexin V- positive cells percentage from the first day of the combined trauma of the chest and both thighs in rats with the highest values within 7-14 days of observation. On 28 day of experiment the reduction of apoptotic white blood cells percentage by 7.7% than the findings on 14 day was observed, but it remained 33.3% higher than control. The analysis of data in case of emoxypine succinate applying indicates that production of reactive oxygen species by leukocytes began to decline after 3 days of experiment and continued to decrease with maximum of action on 7 day.
    [Show full text]